medigraphic.com
Boletín Médico del Hospital Infantil de México

2010, Number 3

<< Back

Bol Med Hosp Infant Mex 2010; 67 (3)

From human proteome to cross-functional personalized medicine

Altamirano BMM, Altamirano BNF, Altamirano BE, Garduño EJ, Muñoz HO, Torres LJ

Language: Spanish
References: 42
Page: 293-302
PDF size: 348.56 Kb.


ABSTRACT

Personalized medicine has led the technological revolution in proteomics into a new phase where appreciation of the values and virtues of the human being are paramount.
Thus we must not forget that the two main reason for personalized medicine are both acknowledgment of the person’s dignity and a tailored diagnosis and treatment of each patient, taking into account not only genes and proteins but also the person’s social background and environment.


REFERENCES

  1. Echeverría J. Tecnociencia y Sistema de Valores. In: López Cerezo J, Sánchez RJ, eds. Ciencia, Tecnología, Sociedad y Cultura en el Cambio de Siglo. Madrid: Biblioteca Nueva, OEA; 2001. pp. 221-230.

  2. Soto C. Protein misfolding and disease; protein refolding and therapy. FEBS Lett 2001;498:204-207.

  3. Fields S. Proteomics in genomeland. Science 2001;291:1221-1224.

  4. Peltonen L, McKusick VA. Dissecting human disease in the postgenomic era. Science 2001;291:1224-1229.

  5. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003;426: 895-899.

  6. Carrell RW, Lomas D. Alpha1-antitrypsin deficiency a model for conformational diseases. N Engl J Med 2002;346:45-52.

  7. Carrell RW, Lomas D. Conformational disease. Lancet 1997;350:134-138.

  8. Altamirano MM, Altamirano N. Tesis dirigida. Especialidad en Pediatría. Las enfermedades conformacionales en Pediatría. Alumno: Javier Martínez Bautista. Facultad de Medicina, UNAM; 2007.

  9. Perutz MF. Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Curr Opinion Struct Biol 1996;6:848-858.

  10. Wright JD. Alzheimer’s disease: an insidious protein conformational disorder. Neuroscience 2003;118:1175-1179.

  11. Hayden MR, Tyagi SC, Kerklo MM, Nicholls MR. Type 2 diabetes mellitus as a conformational disease. J Pancreas 2005;6:287-302.

  12. Kapurniotu A. Amyloidogenicity and cytotoxicity of islet amyloid polypeptide. Biopolymers 2001;60:438-459.

  13. Pepys MB. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Phil Trans R Soc Lond B Biol Sci 2001;356:203-211.

  14. Willard HF, Angrist M, Ginsburg GS. Genomic medicine: genetic variation and its impact on the future of health care. Phil Trans R Soc B 2005;360:1543-1550.

  15. Dobson CM. Protein misfolding, evolution and disease. Trends Biochem Sci 1999;24:329-332.

  16. Zerovnik E. Amyloid-fibril formation. Proposed mechanisms and relevance to conformational disease. Eur J Biochem 2002;269:3362-3371.

  17. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol 2000;130:88-98.

  18. Carrell RW. Cell toxicity and conformational disease. Trends Cell Biol 2005;15:574-580.

  19. Ginsburg GS, Donahue MP, Newby LK. Prospects for personalized cardiovascular medicine: the impact of genomics. J Am Coll Cardiol 2005;46:1615-1627.

  20. Forment Giralt E. Persona y Modo Substancial. Barcelona: PPU; 1984.

  21. Santo Tomás de Aquino. Suma Teológica I, q. 29, a, 3, in c. Available at: http://www.elultimolibro.net/2007/07/santo-toms-de-aquino.html

  22. Santo Tomás de Aquino. Potencia I, q. 9, a. 3, in c. Available at: http://www.elultimolibro.net/2007/07/santo-toms-de-aquino.html

  23. Pellegrino ED. The internal morality of clinical medicine: a paradigm for the ethics of the helping and healing professions. J Med Philos 2001;26:559-579.

  24. Thomasma DC, Kushner T. De la vida a la muerte: Ciencia y Bioética. New York: Cambridge University Press; 1999.

  25. De Solla Price DJ. Little Science, Big Science and Beyond. New York: Columbia University Press; 1986.

  26. Institute for Scientific Information (ISI). Science Citation Index. Philadelphia;1999.

  27. Olivé L. El Bien, el Mal y la Razón. Facetas de la Ciencia y de la Tecnología. México: Paidós-UNAM; 2000.

  28. Sherlock R, Morrey J, eds. Ethical Issues in Biotechnology. New York: Rowman & Littlefield; 2001.

  29. Habermas J. A postscript to “knowledge and human interests”. Phil Social Sci 1973;3:157-189.

  30. Hempel CG. Science and human values. In: Hempel CG. Aspects of Scientific Explanation and Other Essays in the Philosophy of Science. New York: Free Press; 1965.

  31. Latour B. Science in Action: How to Follow Scientists and Engineers Through Society. USA, Milton Keynes: Open University Press; 1987.

  32. Latour B, Woolgar S. Laboratory Life: the Social Construction of Scientific Facts. Beverly Hills, CA: Sage Publications; 1979.

  33. Foung M. Genetic trespassing and environmental ethics. In: Sherlock R, Morrey J, eds. Ethical Issues in Biotechnology. New York: Rowman & Littlefield; 2001

  34. Lacey H. Assessing the value of transgenic crops. Sci Eng Ethics 2002;8:497-511.

  35. Agazzi E. Il Bene, il Male e la Scienza. Le Dimensioni Etiche Dell’impresa Scientifico Tecnologica. Milan: Rusconi; 1992.

  36. Hollinger R. Sciences and values. Introduction. In: Klemke ED, Hollinger R, Wyss RD, eds. Introductory Readings in the Philosophy of Science. New York: Prometheus Books; 1998. p. 481.

  37. Olivé L. El Bien, el Mal y la Razón. Facetas de la Ciencia y de la Tecnología. México: Paidós-UNAM; 2000. pp. 44.

  38. Arrigo JM, Maj-Britt Juhl P. An epistemic model for moral hazards in scientific enterprises. In: Steneck N, Sheetz M, eds. Investigating Research Integrity: Proceedings of the First ORI Research Conference on Research Integrity. Investigating Research Integrity, USA; 2000.

  39. González J. Valores eticos de la ciencia. In: El Poder de Eros. Fundamentos y Valores de Ética y Bioética. México: Paidós; 2005. pp. 227-247.

  40. Olivé L. La Evaluación de Tecnologías y la Formación de Nuevos Tecnólogos. Razón y Sociedad. México: Fontamara; 1996. p. 9.

  41. Menon D, Marshall D. The internationalization of health technology assessment. Int J Technol Assess Health Care 1996;12:45-51.

  42. Juan Pablo II. Fe y Razón, carta encíclica sobre las relaciones entre fe y razón. México: Ediciones Paulinas SA de CV; 1998. p. 114.




2020     |     www.medigraphic.com